Maurizio Perdicchio
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Journal: Nature medicine
Published: March 21, 2025
Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Journal: Journal for immunotherapy of cancer
Published: April 05, 2022
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Journal: Nature
Published: December 08, 2020
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
Journal: Nature communications
Published: May 11, 2018
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.
Journal: Oncoimmunology
Published: March 07, 2016
Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 05, 2016
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.
Journal: Oncoimmunology
Published: April 17, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026